1.Blocking Adenosine/A2AR Pathway for Cancer Therapy.
Jia LIU ; Yuequan SHI ; Xiaoyan LIU ; Dongming ZHANG ; Yu BAI ; Yan XU ; Mengzhao WANG
Chinese Journal of Lung Cancer 2022;25(7):460-467
Adenosine is a metabolite produced abundantly in the tumor microenvironment, dampening immune response in inflamed tissues via adenosine A2A receptor (A2AR) which is widely expressed on immune cells, inhibiting anti-tumor immune response accordingly. Therefore, blocking adenosine signaling pathway is of potential to promote anti-tumor immunity. This review briefly introduces adenosine signaling pathway, describes its role in regulating tumor immunity and highlights A2AR blockade in cancer therapy. Prospective anti-tumor activity of adenosine/A2AR inhibition has been revealed by preclinical data, and a number of clinical trials of A2AR antagonists are under way. Primary results from clinical trials suggest that A2AR antagonists are well tolerated in cancer patients and are effective both as monotherapy and in combination with other therapies. In the future, finding predictive biomarkers are critical to identify patients most likely to benefit from adenosine pathway blockade, and further researches are needed to rationally combine A2AR antagonists with other anti-tumor therapies.
.
Adenosine/therapeutic use*
;
Adenosine A2 Receptor Antagonists/therapeutic use*
;
Humans
;
Lung Neoplasms
;
Receptor, Adenosine A2A/metabolism*
;
Tumor Microenvironment
2.Advances in the study of A2B adenosine receptor antagonists.
Jing WEI ; Wen-Quan YU ; Qing-Zhi GAO
Acta Pharmaceutica Sinica 2008;43(3):241-246
A2B adenosine receptor is involved in the control of mast cell degranulation, interleukin-8 synthesis and cell growth. A2B adenosine receptor antagonists may serve as novel drugs for asthma, Alzheimer' s disease, cystic fibrosis and type-II diabetes. Therefore, seeking for the highly selective A2B adenosine receptor antagonists has been one of great interest. The molecular basis, structure-activity relationship of selective A2B adenosine receptor antagonists and their interactions with A2B adenosine receptor were reviewed.
Adenosine
;
pharmacology
;
Adenosine A2 Receptor Antagonists
;
Adenosine A3 Receptor Antagonists
;
Adenosine-5'-(N-ethylcarboxamide)
;
pharmacology
;
therapeutic use
;
Animals
;
Anti-Asthmatic Agents
;
therapeutic use
;
Asthma
;
drug therapy
;
Humans
;
Pulmonary Artery
;
drug effects
;
Structure-Activity Relationship
;
Xanthines
;
pharmacology